Modulatory Effects of XIAOPI Formula on CXCL1 and Selected Outcomes in Triple-Negative Breast Cancer: A Randomized Controlled Clinical Trial

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Jia H, Truica CI, Wang B, et al. Immunotherapy for triple-negative breast cancer: existing challenges and exciting prospects. Drug Resist Updat. 2017;32:1–15. doi:10.1016/j.drup.2017.07.002
   PubMed Web of Science ®Google Scholar
• Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer. 2010;109(9):1721–1728. doi:10.1002/cncr.22618
   Google Scholar
• Gao C, Li H, Liu C, Xu X, Sun C. Tumor mutation burden and immune invasion characteristics in triple negative breast cancer: Genome high-throughput data analysis. Front Immunol. 2021;12:650491. doi:10.3389/fimmu.2021.650491
   PubMed Web of Science ®Google Scholar
• Leeat K, Marc B, Diana M, et al. A structured tumor-immune microenvironment in triple negative breast cancer revealed by multiplexed ion beam imaging. Cell. 2018;174(6):1373–87.e19. doi:10.1016/j.cell.2018.08.039
   PubMed Web of Science ®Google Scholar
• Wang N, Liu W, Zheng Y, et al. CXCL1 derived from tumor-associated macrophages promotes breast cancer metastasis via activating NF-κB/SOX4 signaling. Cell Death Dis. 2018;9(9):880. doi:10.1038/s41419-018-0876-3
   PubMed Web of Science ®Google Scholar
• Burnier A, Shimizu Y, Dai Y, et al. CXCL1 is elevated in the urine of bladder cancer patients. Springerplus. 2015;4:610. doi:10.1186/s40064-015-1393-9
   PubMedGoogle Scholar
• Xiang Z, Jiang DP, Xia GG, et al. CXCL1 expression is correlated with Snail expression and affects the prognosis of patients with gastric cancer. Oncol Lett. 2015;10(4):2458–2464. doi:10.3892/ol.2015.3614
   PubMed Web of Science ®Google Scholar
• Wang D, Sun H, Wei J, Cen B, DuBois RN. CXCL1 Is Critical for premetastatic niche formation and metastasis in colorectal cancer. Cancer Res. 2017;77(13):3655–3665. doi:10.1158/0008-5472.CAN-16-3199
   PubMed Web of Science ®Google Scholar
• Zhang Z, Chen Y, Jiang Y, Luo Y, Zhang H, Zhan Y. Prognostic and clinicopathological significance of CXCL1 in cancers: a systematic review and meta-analysis. Cancer Biol Ther. 2019;20(11):1380–1388. doi:10.1080/15384047.2019.1647056
   PubMed Web of Science ®Google Scholar
• Swiger KD, Sendecki JA, Guglielmino JE, et al. Abstract P5-17-06: emotional/psychological characteristics of women with triple-negative breast cancer: Do socioeconomic, demographic, and provider variables impact emotional change from diagnosis to post-treatment? Cancer Res. 2015;75(9_Supplement):P5-17-06-P5-17–06. doi:10.1158/1538-7445.SABCS14-P5-17-06
   Google Scholar
• Hass HG, Seywald M, Wöckel A, Muco B, Tanriverdi M, Stepien J. Psychological distress in breast cancer patients during oncological inpatient rehabilitation: incidence, triggering factors and correlation with treatment-induced side effects. Arch Gynecol Obstet. 2023;307(3):919–925. doi:10.1007/s00404-022-06657-3
   PubMed Web of Science ®Google Scholar
• Shen A, Qiang W, Wang Y, Chen Y. Quality of life among breast cancer survivors with triple negative breast cancer--role of hope, self-efficacy and social support. Eur J Oncol Nurs. 2020;46:101771. doi:10.1016/j.ejon.2020.101771
   PubMed Web of Science ®Google Scholar
• Vadaparampil ST, Christie J, Donovan KA, et al. Health-related quality of life in Black breast cancer survivors with and without triple-negative breast cancer (TNBC). Breast Cancer Res Treat. 2017;163(2):331–342. doi:10.1007/s10549-017-4173-0
   PubMed Web of Science ®Google Scholar
• Soucise A, Vaughn C, Thompson CL, et al. Sleep quality, duration, and breast cancer aggressiveness. Breast Cancer Res Treat. 2017;164(1):169–178. doi:10.1007/s10549-017-4245-1
   PubMed Web of Science ®Google Scholar
• Huang M, Haiderali A, Fox GE, et al. Economic and humanistic burden of triple-negative breast cancer: A systematic literature review. Pharmacoeconomics. 2022;40(5):519–558. doi:10.1007/s40273-021-01121-7
   PubMed Web of Science ®Google Scholar
• Wang Y, Li JW, Qin YN, et al. Clinical observation on the effect of Chinese medicine-“TCM formula” intervention on recurrence and metastasis of triple negative breast cancer. Complement Ther Med. 2020;52:102456. doi:10.1016/j.ctim.2020.102456
   PubMed Web of Science ®Google Scholar
• Wang B, Fei R, Yang Y, Jing N, Zhang Y. The Shuganhuazheng formula in triple-negative breast cancer: a study based on network pharmacology and in vivo experiments. Evid Based Complement Alternat Med. 2020;2020(2):1–10.
   Google Scholar
• Wang J, Yang X, Han H, Wang L, Hu K. Inhibition of growth and metastasis of triple-negative breast cancer targeted by Traditional Chinese Medicine Tubeimu in orthotopic mice models. Chin J Cancer Res. 2018;30(1):112. doi:10.21147/j.issn.1000-9604.2018.01.12
   PubMed Web of Science ®Google Scholar
• Yang Z, Zhang Q, Yu L, Zhu J, Gao X, Gao X. The signaling pathways and targets of traditional Chinese medicine and natural medicine in triple-negative breast cancer. J Ethnopharmacol. 2020;264:113249. doi:10.1016/j.jep.2020.113249
   PubMed Web of Science ®Google Scholar
• Wang Y, Liu SY, Zhang Y, et al. Effect of traditional Chinese medicine on postoperative depression of breast cancer: a systematic review and meta-analysis. Front Pharmacol. 2023;23(14):1019049. doi:10.3389/fphar.2023.1019049
   Google Scholar
• Bai X, Ta N, Gong GH, Zhang B, Wei CX, Emran TB. Effects of integrated Chinese traditional medicine and conventional western medicine on the quality of life of breast cancer patients: a systematic review and meta-analysis. Evid Based Complement Alternat Med. 2022;2022:3123878. doi:10.1155/2022/3123878
   PubMed Web of Science ®Google Scholar
• Zou J, Bian W, Ren X, Liu F. Clinical research of xiaopi granule in treating hyperplasia of mammary glands with phlegm and blood stasis and chong ren dysfunction syndrome. World Chin Med. 2013;8(12):1439–1441.
   Google Scholar
• Zheng Y, Wang N, Wang S, Yang B, Wang ZJB. XIAOPI formula inhibits the pre-metastatic niche formation in breast cancer via suppressing TAMs/CXCL1 signaling. Cell Commun Signal. 2020;18(1):48. doi:10.1186/s12964-020-0520-6
   PubMed Web of Science ®Google Scholar
• Wang N, Yang B, Muhetaer G, Wang S, Wang Z. XIAOPI formula promotes breast cancer chemosensitivity via inhibiting CXCL1/HMGB1-mediated autophagy. Biomed Pharmacother. 2019;120:109519. doi:10.1016/j.biopha.2019.109519
   PubMed Web of Science ®Google Scholar
• Wang S, Liu X, Huang R, et al. XIAOPI formula inhibits breast cancer stem cells via suppressing tumor-associated macrophages/C-X-C Motif Chemokine Ligand 1 Pathway. Front Pharmacol. 2019;10:1371. doi:10.3389/fphar.2019.01371
   PubMed Web of Science ®Google Scholar
• William WK Zung. A Rating Instrument for Anxiety Disorders. Psychosomatics. 1971;12(6): 371–379. doi:10.1016/S0033-3182(71)71479-0
   PubMed Web of Science ®Google Scholar
• William WK Zung. A Self-Rating Depression Scale. Arch Gen Psychiatry. 1965;12:63–70. doi:10.1001/archpsyc.1965.01720310065008
   PubMed Web of Science ®Google Scholar
• Brady M.J., Cella D.F., Mo F. Reliability and validity of the Functional Assessment of Cancer Therapy – Breast quality-of-life instrument. Journal of Clinical Oncology. 1997;15(3):974–986. doi:10.1200/JCO.1997.15.3.974
   PubMed Web of Science ®Google Scholar
• Buysse DJ, Reynolds CF, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989;28(2):193–213. doi:10.1016/0165-1781(89)90047-4
   PubMed Web of Science ®Google Scholar
• Pilevarzadeh M, Amirshahi M, Afsargharehbagh R, Rafiemanesh H, Hashemi SM, Balouchi A. Global prevalence of depression among breast cancer patients: a systematic review and meta-analysis. Breast Cancer Res Treat. 2019;176(3):519–533. doi:10.1007/s10549-019-05271-3
   PubMed Web of Science ®Google Scholar
• Hashemi SM, Rafiemanesh H, Aghamohammadi T, et al. Prevalence of anxiety among breast cancer patients: a systematic review and meta-analysis. Breast Can. 2020;27(2):166–178. doi:10.1007/s12282-019-01031-9
   PubMed Web of Science ®Google Scholar
• Wang X, Wang N, Zhong L, et al. Prognostic value of depression and anxiety on breast cancer recurrence and mortality: a systematic review and meta-analysis of 282,203 patients. Mol Psychiatry. 2020;25(12):3186–3197. doi:10.1038/s41380-020-00865-6
   PubMed Web of Science ®Google Scholar
• Fox RS, Ancoli-Israel S, Roesch SC, et al. Sleep disturbance and cancer-related fatigue symptom cluster in breast cancer patients undergoing chemotherapy. Supt Care Cancer. 2020;28(2):845–855. doi:10.1007/s00520-019-04834-w
   PubMed Web of Science ®Google Scholar
• El Kherchi O, Aquil A, Elkhoudri N, et al. Relationship between sleep quality and anxiety-depressive disorders in Moroccan women with breast cancer: a cross-sectional study. Iran J Public Health. 2023;52(7):1457–1465. doi:10.18502/ijph.v52i7.13247
   PubMed Web of Science ®Google Scholar
• Lam CS, Yu BY, Cheung DST, et al. Sleep and Mood Disturbances during the COVID-19 Outbreak in an Urban Chinese Population in Hong Kong: a Longitudinal Study of the Second and Third Waves of the Outbreak. Int J Environ Res Public Health. 2021;18(16):8444. doi:10.3390/ijerph18168444
   PubMed Web of Science ®Google Scholar
• Donneyong MM, Bykov K, Bosco-Levy P, Dong YH, Levin R, Gagne JJ. Risk of mortality with concomitant use of tamoxifen and selective serotonin reuptake inhibitors: multi-database cohort study. BMJ. 2016;354:i5014. doi:10.1136/bmj.i5014
   PubMed Web of Science ®Google Scholar
• Carina R, Tibor S, Kristian B, Sarah M, Jürgen W, Siepmann T. Adverse Effects of Antidepressants for Chronic Pain: a Systematic Review and Meta-analysis. Front Neurol. 2017;8:307. doi:10.3389/fneur.2017.00307
   PubMed Web of Science ®Google Scholar
• Deng HY, Wu SP, Wu XF, Liu D. Clinical study of Chaihu Shugan Powder in the treatment of cancer-related depression. Int J Trad Chin Med. 2022;44(2):150–153.
   Google Scholar
• Jiao J, Luo KH, Li YH, Li DF, Ang JY T. Clinical Observation on Modified Xiaoyao Powder Treatment for patients with depression syndrome of liver depression and spleen deficiency during adjuvant chemotherapy after breast cancer operation. Anti-Tumor Pharmacy. 2019;9(1):107–111.
   Google Scholar
• Liu XF, Zhang X, Jing K. Observational study on the efficacy of needle warming moxibustion in edema of the upper extremity and anxiety-depression of mammary cancer patients after operation. World Chinese Med. 2019;14(7):1856–1860.
   Google Scholar
• WKW S, Law BMH, MSN N, et al. Symptom clusters experienced by breast cancer patients at various treatment stages: a systematic review. Cancer Med. 2021;10(8):2531–2565. doi:10.1002/cam4.3794
   PubMed Web of Science ®Google Scholar
• Bidstrup PE, Christensen J, Mertz BG, Rottmann N, Dalton SO, Johansen C. Trajectories of distress, anxiety, and depression among women with breast cancer: looking beyond the mean. Acta Oncol. 2015;54(5):789–796. doi:10.3109/0284186X.2014.1002571
   PubMed Web of Science ®Google Scholar
• Heo J, Chun M, Oh YT, Noh OK, Kim L. Psychiatric comorbidities among breast cancer survivors in South Korea: a nationwide population-based study. Breast Cancer Res Treat. 2017;162(1):151–158. doi:10.1007/s10549-016-4097-0
   PubMed Web of Science ®Google Scholar
• Carreira H, Williams R, Müller M, Harewood R, Stanway S, Bhaskaran K. Associations Between Breast Cancer Survivorship and Adverse Mental Health Outcomes: a Systematic Review. J Natl Cancer Inst. 2018;110(12):1311–1327. doi:10.1093/jnci/djy177
   PubMedGoogle Scholar
• Grocott B, Reynolds K, Logan G, Hebbard P, El-Gabalawy R. Breast cancer patient experiences of perioperative distress and anxiety: a qualitative study. Eur J Oncol Nurs. 2023;63:102299. doi:10.1016/j.ejon.2023.102299
   PubMed Web of Science ®Google Scholar
• Fortunato L, Loreti A, Cortese G, et al. Regret and quality of life after mastectomy with or without reconstruction. Clin Breast Cancer. 2021;21(3):162–169. doi:10.1016/j.clbc.2019.11.005
   PubMed Web of Science ®Google Scholar
• Grilo AM, Gomes AI, Monsanto F, Albino D, Augusto C, Pragana C. First day of radiotherapy for women with breast cancer: predictors of anxiety. Supt Care Cancer. 2020;28(3):1241–1248. doi:10.1007/s00520-019-04902-1
   PubMed Web of Science ®Google Scholar
• Lv D, Lan B, Zhang L, Sun X, Yang M, Ma F. Association between depression and anxiety status of breast cancer patients before adjuvant chemotherapy and chemotherapy-induced adverse events. Cancer Med. 2023;12(4):4794–4800. doi:10.1002/cam4.5283
   PubMed Web of Science ®Google Scholar
• Keene MR, Heslop IM, Sabesan SS, Glass BD. Complementary and alternative medicine use in cancer: a systematic review. Comp Ther Clin Pract. 2019;35:33–47. doi:10.1016/j.ctcp.2019.01.004
   PubMed Web of Science ®Google Scholar
• Naing A, Stephen SK, Frenkel M, et al. Prevalence of complementary medicine use in a Phase 1 clinical trials program. Cancer. 2011;117(22):5142–5150. doi:10.1002/cncr.26164
   PubMed Web of Science ®Google Scholar
• Zhou R, Zheng Y, An X, Jin D, Lian F, Tong X. Dosage modification of traditional Chinese medicine prescriptions: An analysis of two randomized controlled trials. Front Pharmacol. 2021;12:732698. doi:10.3389/fphar.2021.732698
   PubMed Web of Science ®Google Scholar
• Li Z, Deng H, Guo X, et al. Effective dose/duration of natural flavonoid quercetin for treatment of diabetic nephropathy: a systematic review and meta-analysis of rodent data. Phytomedicine. 2022;105:154348. doi:10.1016/j.phymed.2022.154348
   PubMed Web of Science ®Google Scholar